Protagonist Therapeutics (NASDAQ:PTGX) Director Sells $1,483,560.00 in Stock

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Director Lewis Williams sold 18,000 shares of the business’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $82.42, for a total transaction of $1,483,560.00. Following the sale, the director directly owned 7,825 shares in the company, valued at $644,936.50. The trade was a 69.70% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Protagonist Therapeutics Stock Performance

Shares of NASDAQ PTGX opened at $82.76 on Friday. The company has a 50 day simple moving average of $84.36 and a two-hundred day simple moving average of $75.62. Protagonist Therapeutics, Inc. has a fifty-two week low of $33.70 and a fifty-two week high of $96.54. The company has a market capitalization of $5.17 billion, a price-to-earnings ratio of 133.49 and a beta of 2.26.

Analyst Ratings Changes

A number of equities research analysts have recently commented on PTGX shares. Barclays increased their target price on Protagonist Therapeutics from $88.00 to $108.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 17th. Citigroup increased their price objective on shares of Protagonist Therapeutics from $98.00 to $115.00 and gave the company a “buy” rating in a research report on Monday, December 8th. BTIG Research restated a “buy” rating and set a $82.00 price objective on shares of Protagonist Therapeutics in a research note on Tuesday, October 28th. Jefferies Financial Group upped their target price on shares of Protagonist Therapeutics from $95.00 to $118.00 and gave the stock a “buy” rating in a research note on Monday, February 2nd. Finally, Weiss Ratings cut shares of Protagonist Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Protagonist Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $93.38.

Institutional Trading of Protagonist Therapeutics

Large investors have recently made changes to their positions in the stock. American Century Companies Inc. raised its stake in Protagonist Therapeutics by 18.7% during the 2nd quarter. American Century Companies Inc. now owns 813,995 shares of the company’s stock valued at $44,990,000 after buying an additional 128,171 shares during the last quarter. Voya Investment Management LLC grew its holdings in shares of Protagonist Therapeutics by 8.9% in the third quarter. Voya Investment Management LLC now owns 305,419 shares of the company’s stock worth $20,289,000 after acquiring an additional 25,065 shares during the period. Segall Bryant & Hamill LLC purchased a new stake in Protagonist Therapeutics during the second quarter valued at $6,641,000. Nan Fung Trinity HK Ltd. bought a new position in Protagonist Therapeutics in the second quarter valued at about $7,464,000. Finally, Bank of New York Mellon Corp lifted its holdings in Protagonist Therapeutics by 3.0% in the second quarter. Bank of New York Mellon Corp now owns 388,082 shares of the company’s stock valued at $21,449,000 after acquiring an additional 11,219 shares during the period. 98.63% of the stock is currently owned by institutional investors.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.